Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled Trial

View ORCID ProfileRaburn Mallory, Neil Formica, Susan Pfeiffer, Bethanie Wilkinson, Alex Marcheschi, Gary Albert, Heather McFall, Michelle Robinson, Joyce S. Plested, Mingzhu Zhu, Shane Cloney-Clark, Bin Zhou, Gordon Chau, Andreana Robertson, Sonia Maciejewski, Gale Smith, Nita Patel, Gregory M. Glenn, Filip Dubovsky, for the Novavax Inc. 2019nCoV-101 Study Group
doi: https://doi.org/10.1101/2021.12.23.21267374
Raburn Mallory
Novavax, Inc
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Raburn Mallory
  • For correspondence: RMallory@novavax.com
Neil Formica
Novavax, Inc
M.B.B.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan Pfeiffer
Novavax, Inc
P.A-C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bethanie Wilkinson
Novavax, Inc
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alex Marcheschi
Novavax, Inc
Pharm.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gary Albert
Novavax, Inc
M.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heather McFall
Novavax, Inc
M.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle Robinson
Novavax, Inc
M.P.H.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joyce S. Plested
Novavax, Inc
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mingzhu Zhu
Novavax, Inc
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shane Cloney-Clark
Novavax, Inc
B.Sc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bin Zhou
Novavax, Inc
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gordon Chau
Novavax, Inc
M.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreana Robertson
Novavax, Inc
M.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sonia Maciejewski
Novavax, Inc
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gale Smith
Novavax, Inc
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nita Patel
Novavax, Inc
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory M. Glenn
Novavax, Inc
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Filip Dubovsky
Novavax, Inc
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Novavax, Inc
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Article usage

Article usage: December 2021 to November 2023

AbstractFullPdf
Dec 2021492771707
Jan 202231924571101
Feb 202251543301733
Mar 20221332186572
Apr 2022625172338
May 2022803132404
Jun 2022651108688
Jul 202281882263
Aug 2022544112105
Sep 20225173852
Oct 202239047176
Nov 20222381932
Dec 20222991635
Jan 2023507625
Feb 20232321927
Mar 20231271522
Apr 20231711116
May 2023107419
Jun 2023144811
Jul 2023117915
Aug 2023871914
Sep 20231591326
Oct 202311832417
Nov 2023713689
Back to top
PreviousNext
Posted December 25, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled Trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled Trial
Raburn Mallory, Neil Formica, Susan Pfeiffer, Bethanie Wilkinson, Alex Marcheschi, Gary Albert, Heather McFall, Michelle Robinson, Joyce S. Plested, Mingzhu Zhu, Shane Cloney-Clark, Bin Zhou, Gordon Chau, Andreana Robertson, Sonia Maciejewski, Gale Smith, Nita Patel, Gregory M. Glenn, Filip Dubovsky, for the Novavax Inc. 2019nCoV-101 Study Group
medRxiv 2021.12.23.21267374; doi: https://doi.org/10.1101/2021.12.23.21267374
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled Trial
Raburn Mallory, Neil Formica, Susan Pfeiffer, Bethanie Wilkinson, Alex Marcheschi, Gary Albert, Heather McFall, Michelle Robinson, Joyce S. Plested, Mingzhu Zhu, Shane Cloney-Clark, Bin Zhou, Gordon Chau, Andreana Robertson, Sonia Maciejewski, Gale Smith, Nita Patel, Gregory M. Glenn, Filip Dubovsky, for the Novavax Inc. 2019nCoV-101 Study Group
medRxiv 2021.12.23.21267374; doi: https://doi.org/10.1101/2021.12.23.21267374

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (280)
  • Allergy and Immunology (577)
  • Anesthesia (139)
  • Cardiovascular Medicine (1942)
  • Dentistry and Oral Medicine (252)
  • Dermatology (183)
  • Emergency Medicine (331)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (697)
  • Epidemiology (11086)
  • Forensic Medicine (8)
  • Gastroenterology (619)
  • Genetic and Genomic Medicine (3156)
  • Geriatric Medicine (307)
  • Health Economics (560)
  • Health Informatics (2037)
  • Health Policy (861)
  • Health Systems and Quality Improvement (781)
  • Hematology (309)
  • HIV/AIDS (682)
  • Infectious Diseases (except HIV/AIDS) (12702)
  • Intensive Care and Critical Care Medicine (707)
  • Medical Education (317)
  • Medical Ethics (92)
  • Nephrology (334)
  • Neurology (2977)
  • Nursing (162)
  • Nutrition (461)
  • Obstetrics and Gynecology (589)
  • Occupational and Environmental Health (614)
  • Oncology (1548)
  • Ophthalmology (474)
  • Orthopedics (185)
  • Otolaryngology (265)
  • Pain Medicine (201)
  • Palliative Medicine (57)
  • Pathology (402)
  • Pediatrics (909)
  • Pharmacology and Therapeutics (381)
  • Primary Care Research (354)
  • Psychiatry and Clinical Psychology (2774)
  • Public and Global Health (5583)
  • Radiology and Imaging (1090)
  • Rehabilitation Medicine and Physical Therapy (630)
  • Respiratory Medicine (755)
  • Rheumatology (338)
  • Sexual and Reproductive Health (311)
  • Sports Medicine (287)
  • Surgery (342)
  • Toxicology (48)
  • Transplantation (159)
  • Urology (131)